The SA Journal Diabetes & Vascular Disease Vol 13 No 2 (December 2016)

46 / 52

96 VOLUME 13 NUMBER 2 • DECEMBER 2016
REVIEW SA JOURNAL OF DIABETES & VASCULAR DISEASE
27. Elmahdi EM, Kaballo AM, Mukhtar EA. Features of non-insulindependent
diabetes mellitus (NIDDM) in the Sudan. Diabetes Res Clin Pract 1991; 11:
59–63.
28. Mbanya JC, Sobngwi E. Diabetes microvascular and macrovascular disease in
Africa. J Cardiovasc Risk 2003; 10: 97–102.
29. Mhando PA, Yudkin JS. The pattern of diabetic complications in African patients
in Dar es Salaam. Trop Geogr Med 1980; 32: 317–323.
30. Lester FT, Keen H. Macrovascular disease in middle-aged diabetic patients in
Addis Ababa, Ethiopia. Diabetologia 1988; 31: 361–367.
31. World Health Organization: WHO Global Infobase: int/
infobase/Indicators.aspx (Accesses 28 December 2011).
32. Bovet P, William J, Viswarathan B, Madeleine G, Romain S, Yerly P, et al. The
Seychelles Heart Study 2004; Ministry of Health and Social Development. http://
www.who.int/chp/steps/2004_STEPS_Report_ Seychelles.pdf (Accessed 28
December 2011).
33. Pampel F. Tobacco use in sub-Saharan Africa: Estimates from the demographic
health survey. Soc Sci Med 2008; 66(8): 1772–1783.
34. Ezzati M, Lopez AD. Regional, disease-specific patterns of smokingattributable
mortality in 2000. Tobacco Control 2004; 13: 388–395.
35. Rolfe M, Mendelsohn D, Armstrong JRM. Lipid levels in diabetic patients from
Central Africa. Int Diabetes Digest 1993; 4: 154–157.
36. Anaja HP, Isah HS, Abdu-Aguye I, Oburu NA. Lipid profiles in diabetic Nigerians:
a Zaria update. Int Diabetes Digest 1995; 6(4): 90–93.
37. Vorster HH. The emergence of cardiovascular disease during urbanisation of
Africans. Public Health Nutr 2002; 5: 239–243.
38. Kadiri S, Salako BL. Cardiovascular risk factors in middle aged Nigerians. East
Afr Med J 1997; 74(5): 303–306.
39. Mollentze WF, More AJ, Steyn AF, Joubert G, Steyn K, Oosthuizen GM, et al.
Coronary heart disease risk factors in a rural and urban Orange Free State black
population. S Afr Med J 1995; 85(2): 90–96.
40. National AIDS Coordinating Agency, Botswana. Progress report of the national
response to the 2001 Declaration of Commitment on HIV and AIDS: Botswana
country report 2010. Gaborone, Ministry of Health, 2010.
41. Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med 2007;
356: 2073.
42. Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, Malincarne
L, Gresele P. HIV type 1 infection, and not short-termHAART, induces endothelial
dysfunction. AIDS 2009; 23(5): 589.
43. Baker JV, Duprez D, Rapkin J, Hullsiek KH, Quick H, Grimm R, et al. Untreated
HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr
2009; 52(1): 25.
44. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV
infection on endothelial function. Endothelium 2000; 7(4): 223.
45. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et
al. Traditional risk factors and D-dimer predict incident cardiovascular disease
events in chronic HIV infection. AIDS 2010; 24 (10): 1509.
46. Seigneur M, Constans J, Blann A, Renard M, Pellegrin JL, Amiral J, et al. Soluble
adhesion molecules and endothelial cell damage in HIV infected patients.
Thromb Haemost 1997; 77(4): 646.
47. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased
prevalence of subclinical coronary atherosclerosis detected by coronary computed
tomography angiography in HIV-infected men. AIDS 2010; 24(2): 243.
48. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids,
lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency
virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol
Metab 1992; 74(5): 1045.
49. Dorrington R, Bourne D, Bradshaw D, Laubscher R, Timaeus IM. The impact
of HIV/AIDS on adult mortality in South Africa. Technical Report. Cape Town:
Burden of Disease Research Unit, Medical Research Council, 2001.
50. Kengne AP, Amoah AGM, Mbanya J-C. Cardiovascular complications of diabetes
mellitus in sub-Saharan Africa. Circulation 2005; 112: 3592–3601.
51. Steyn K, Sliwa K, Hawkens S, Commerford P, Onen C, Damasceno A, et al. Risk
Factors associated with myocardial infarction in Africa: The INTERHEART Africa
Study. Circulation 2005; 112(23): 3554–3561.
52. Ezzati M, Vander Hoorn S, Lopez AD, et al. Comparative quantification of
mortality and burden of disease attributable to selected risk factors. In: Lopez
AD, Mathers CD, Ezzati M, et al . (eds). Global Burden of Disease and Risk
Factors. New York: Oxford University Press, 2006: 241–396.
53. Joubert J, McLean CA, Reid CM, Davel D, Pilloy W, Delport R, et al. Ischemic
heart disease in black South African stroke patients. Stroke 2000; 31: 1294–
1298.
54. Grusin H. Peculiarities of the African’s electrocardiogram and the changes
observed in serial studies. Circulation 1954; 9: 860–869.
55. Walker ARP, Walker BF. The bearing of race, age, sex and nutritional state on
the precordial electrocardiogram of young South African Bantu and Caucasian
subjects. Am Heart J 1969; 77: 441–459.
56. Ashcroft MT. Problems in interpreting electrocardiograms (ECGs) and
questionnaires for effort pain in rural Jamaica. West Indian Med J 1976; 300:
1350.
57. Przybojewski JZ, Becker PH. ‘Pseudonormalisation’ of the ‘normal variant
pattern’ on the ECG of black subjects after intermittent acute myocardial
ischaemia: a case report. S Afr Med J 1987; 24: 110–113.
58. Norman R, Bradshaw D, Schneider M, Pieterse D, Groenewald P. Revised Burden
of disease estimates for the comparative risk factor assessment, South Africa
2000. Cape Town: Medical Research Council, 2006.
59. Seedat YK. Review: Diabetes mellitus in South African Indians. Br J Diabetes
Vasc Dis 2005; 5(5): 249–251.
60. Motala AA, Pirie F, Gouws E, Amod A, Omar MAK. High incidence of type 2
diabetes mellitus in South African Indians: a 10-year follow-up study. Diabet
Med 2003; 20: 23–30.
61. Omar MAK , R Seedat MA, Dyer RB, Motala AA, Knight LT, Becker PJ South
African Indians show a high prevalence of NIDDM and bimodality in plasma
glucose distribution. Diabetes Care 1994; 17: 70–73.
62. Bradshaw D, Groenewald P, Laubscher R, Nannan N, Nojilana B, Norman R,
et al. Initial burden of disease estimates for South Africa 2000. Cape Town:
South African Medical Research Council, 2003. URL:
bod/initialbodestimates.pdf (Accessed 28 December 2011).
63. World Health Organization. bod_
deathbyregion.xls (Accessed 28 December 2011).
64. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al .
Antiretroviral therapy exposure and incidence of diabetes mellitus in the
Women’s Interagency HIV Study. AIDS 2007; 21(13): 1739.
65. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative
exposure to nucleoside analogue reverse transcriptase inhibitors is associated
with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS
2005; 19(13): 1375.
66. Bradlow BA, Zion MM, Fleishman SJ. Heart disease in Africa, with particular
reference to Southern Africa. Am J Cardiol 1964; 13: 650–669.
C A R V E D I L O L 6,25 mg 12,5 mg 25 mg
RESTORE
cardiac function
Carvetrend 6,25 mg.Each tablet contains 6,25 mg carvedilol. Reg. No.: RSA S3 37/7.1.3/0276 NAM NS2
08/7.1.3/0105 BOT S2 BOT1101790. Carvetrend 12,5 mg.Each tablet contains 12,5 mg carvedilol. Reg. No.:
RSA S3 37/7.1.3/0277 NAM NS2 08/7.1.3/0104 BOT S2 BOT1101791. Carvetrend 25 mg. Each tablet contains
25 mg carvedilol. Reg. No.: RSA S3 37/7.1.3/0278 NAM NS2 08/7.1.3/0103 BOT S2 BOT1101792. For full
prescribing information, refer to the package insert approved by the Medicines Control Council, 16 September
2004. CDD123/07/2015.
ß
CUSTOMER CARE LINE 0860 PHARMA (742 762)
A Lupin Group Company